Table 2. The expression of miR-34a, BRCA1, BRCA2 and p53 in Estrogen Receptor (ER), Progesterone Receptor (PR), and Human epidermal growth factor receptor 2 (HER2/neu) female patients in the different subtypes and clinical stages of breast cancer, pre- and post-chemotherapy (Mean ± SD). The numbers between brackets represent the number of patients.
| miR-34a | BRCA1 | BRCA2 | p53 | |||||
|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| Estrogen Receptor (ER) | ||||||||
| Positive (112) | −15.03 ± 0.63 | −8.47 ± 0.99* | −16.99 ± 1.22 | −10.89 ± 1.08* | −13.17 ± 0.57 | −7.16 ± 0.79* | −13.46 ± 1.02 | −5.50 ± 1.08 |
| Negative (67) | −15.87 ± 0.91 | −11.82 ± 2.84* | −19.35 ± 1.84 | −16.58 ± 3.81 | −15.96 ± 1.73 | −12.29 ± 3.52* | −15.55 ± 2.12 | −10.41 ± 2.28* |
| Progesterone Receptor (PR) | ||||||||
| Positive (106) | −15.00 ± 0.64 | −8.44 ± 0.98* | −16.97 ± 1.22 | −10.90 ± 1.11* | −13.17 ± 0.58 | −7.16 ± 0.81* | −13.44 ± 1.03 | −5.48 ± 1.07* |
| Negative (73) | −15.81 ± 0.91 | −11.58 ± 2.85* | −19.18 ± 1.88 | −16.10 ± 3.99 | −15.73 ± 1.82 | −11.88 ± 3.65* | −15.39 ± 2.10 | −10.03 ± 2.31* |
| Human epidermal growth factor receptor 2 (HER2/neu) | ||||||||
| Positive (63) | −15.00 ± 0.67 | −8.41 ± 1.15* | −17.01 ± 1.25 | −10.89 ± 1.28* | −13.24 ± 0.63 | −7.25 ± 0.99* | −13.44 ± 1.07 | −5.45 ± 1.25* |
| Negative (116) | −15.53 ± 0.88 | −10.44 ± 2.73* | −18.34 ± 1.99 | −14.17 ± 4.07* | −14.74 ± 1.96 | −10.08 ± 3.73* | −14.67 ± 2.00 | −8.36 ± 4.08* |
| Subtypes | ||||||||
| Luminal A (66) | −15.09 ± 0.61 | −8.51 ± 0.79* | −16.91 ± 1.18 | −10.86 ± 0.73* | −13.17 ± 0.51 | −7.08 ± 0.37* | −13.44 ± 0.97 | −5.45 ± 0.77* |
| Luminal B (47) | −14.93 ± 0.67 | −8.43 ± 1.22* | −17.10 ± 1.27 | −10.92 ± 1.43* | −13.18 ± 0.66 | −7.28 ± 1.14* | −13.49 ± 1.08 | −5.56 ± 1.39* |
| HER2/neu (16) | −15.22 ± 0.65 | −8.34 ± 0.95* | −16.75 ± 1.17 | −10.82 ± 0.71* | −13.43 ± 0.50 | −7.16 ± 0.22* | −13.29 ± 1.06 | −5.11 ± 0.58* |
| Basal Like (50) | −16.11 ± 0.86 | −12.99 ± 2.25 | −20.23 ± 1.04 | −18.55 ± 1.97 | −16.81 ± 1.00 | −14.04 ± 2.09 | −16.31 ± 1.84 | −12.21 ± 3.42* |
| Clinical Stage | ||||||||
| I (12) | −15.12 ± 0.65 | −7.99 ± 0.64* | −15.40 ± 0.40 | −10.66 ± 0.65* | −13.25 ± 0.67 | −7.03 ± 0.24* | −13.67 ± 1.01 | −5.11 ± 0.60* |
| II (135) | −15.20 ± 0.79 | −9.16 ± 2.07* | −17.39 ± 1.31 | −11.77 ± 2.65* | −13.65 ± 1.36 | −8.09 ± 2.61* | −13.83 ± 1.53 | −6.48 ± 2.90* |
| III (32) | −16.03 ± 0.84 | −12.77 ± 2.23 | −20.83 ± 0.52 | −19.16 ± 0.81 | −16.96 ± 0.62 | −14.04 ± 1.88 | −16.17 ± 1.99 | −11.80 ± 3.71* |
Note: * Post-chemotherapy is significant as compared to pre-chemotherapy at the 0.05 level.